JP2016515623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515623A5 JP2016515623A5 JP2016506607A JP2016506607A JP2016515623A5 JP 2016515623 A5 JP2016515623 A5 JP 2016515623A5 JP 2016506607 A JP2016506607 A JP 2016506607A JP 2016506607 A JP2016506607 A JP 2016506607A JP 2016515623 A5 JP2016515623 A5 JP 2016515623A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid pharmaceutical
- pharmaceutical formulation
- furosemide
- aminomethane
- hydroxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 10
- 229960003883 furosemide Drugs 0.000 claims 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 10
- 239000000872 buffer Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808962P | 2013-04-05 | 2013-04-05 | |
| US61/808,962 | 2013-04-05 | ||
| PCT/US2014/032800 WO2014165660A1 (en) | 2013-04-05 | 2014-04-03 | Pharmaceutical formulations for subcutaneous administration of furosemide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018187299A Division JP6677779B2 (ja) | 2013-04-05 | 2018-10-02 | フロセミドの皮下投与用の医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515623A JP2016515623A (ja) | 2016-05-30 |
| JP2016515623A5 true JP2016515623A5 (enExample) | 2017-05-18 |
| JP6415535B2 JP6415535B2 (ja) | 2018-10-31 |
Family
ID=51659206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506607A Active JP6415535B2 (ja) | 2013-04-05 | 2014-04-03 | フロセミドの皮下投与用の医薬製剤 |
| JP2018187299A Active JP6677779B2 (ja) | 2013-04-05 | 2018-10-02 | フロセミドの皮下投与用の医薬製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018187299A Active JP6677779B2 (ja) | 2013-04-05 | 2018-10-02 | フロセミドの皮下投与用の医薬製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9884039B2 (enExample) |
| EP (3) | EP2981258B8 (enExample) |
| JP (2) | JP6415535B2 (enExample) |
| KR (2) | KR102493735B1 (enExample) |
| CN (1) | CN105431145B (enExample) |
| AU (1) | AU2014248164B2 (enExample) |
| CA (1) | CA2908935C (enExample) |
| DK (1) | DK2981258T3 (enExample) |
| ES (1) | ES2823589T3 (enExample) |
| IL (1) | IL241917B (enExample) |
| MX (1) | MX367165B (enExample) |
| PT (1) | PT2981258T (enExample) |
| SG (2) | SG10201709388QA (enExample) |
| WO (1) | WO2014165660A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9884039B2 (en) | 2013-04-05 | 2018-02-06 | Scpharmaceuticals Inc. | Pharmaceutical formulations for subcutaneous administration of furosemide |
| DE102014115951A1 (de) * | 2014-11-03 | 2016-05-04 | Merlion Pharmaceuticals Pte Ltd. | Zusammensetzungen, die Finafloxacin und Tris enthalten |
| US12403120B2 (en) * | 2018-12-10 | 2025-09-02 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| EP3906019B1 (en) | 2019-01-04 | 2025-11-26 | SQ Innovation AG | Pharmaceutical compositions of furosemide |
| EP3906020B1 (en) | 2019-01-04 | 2025-12-31 | SQ Innovation AG | Pharmaceutical compositions of torsemide and their uses |
| CA3128033A1 (en) * | 2019-01-31 | 2020-08-06 | Scpharmaceuticals Inc. | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| WO2022031959A1 (en) | 2020-08-05 | 2022-02-10 | Scpharmaceuticals Inc. | Methods of treatment using furosemide |
| JP2024512650A (ja) | 2021-04-02 | 2024-03-19 | エスシーファーマシューティカルズ インコーポレイテッド | フロセミドの皮下注入 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663348A (en) | 1985-07-02 | 1987-05-05 | Warner-Lambert Co. | Furosemide salts and pharmaceutical preparations thereof |
| US4698361A (en) | 1986-05-28 | 1987-10-06 | Schiena Michele G Di | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same |
| DE3623620A1 (de) * | 1986-07-12 | 1988-01-21 | Boehringer Mannheim Gmbh | Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung |
| ATE181965T1 (de) * | 1991-05-30 | 1999-07-15 | Abbott Lab | Reagenzien, die einen nichtspezifischen bindungshemmer in einem ioneneinfang-assay enthalten |
| US5633240A (en) | 1994-09-01 | 1997-05-27 | Academic Pharmaceuticals | Parenteral solutions containing metolazone |
| EP1201248A3 (en) * | 1995-02-10 | 2002-05-08 | G.D. Searle & Co. | Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease |
| IT1283608B1 (it) * | 1996-04-17 | 1998-04-22 | Ricerche Di Schiena Snc Di Dr | Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva. |
| CN1068778C (zh) | 1998-05-15 | 2001-07-25 | 赵超英 | 救治用的药物组合物及其制备方法 |
| PL1803934T3 (pl) | 2005-12-28 | 2009-03-31 | Sensile Pat Ag | Mikropompa |
| HUE032274T2 (en) * | 2006-07-12 | 2017-09-28 | Univ Tennessee Res Found | Substituted acetanilides and methods of their application |
| EP2022518A1 (en) | 2007-08-07 | 2009-02-11 | Sensile Pat AG | Modular drug delivery device for administering discrete doses of a medicament |
| US7923447B2 (en) * | 2008-03-17 | 2011-04-12 | Academic Pharmaceuticals Incorporated | Parenteral solutions containing metolazone |
| WO2009140659A2 (en) | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of treating dyspnea associated with acute heart failure |
| MX340669B (es) * | 2008-09-09 | 2016-07-20 | Cima Labs Inc | Formas farmaceuticas para compuestos debilmente ionizables. |
| EP2473226A1 (en) * | 2009-09-04 | 2012-07-11 | Minipumps LLC | Adhesive skin patch with pump for subcutaneous drug delivery |
| EP2768514B8 (en) | 2011-10-19 | 2019-06-19 | Mercator Medsystems, Inc. | Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation |
| US9884039B2 (en) * | 2013-04-05 | 2018-02-06 | Scpharmaceuticals Inc. | Pharmaceutical formulations for subcutaneous administration of furosemide |
| US12403120B2 (en) * | 2018-12-10 | 2025-09-02 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| EP3906019B1 (en) * | 2019-01-04 | 2025-11-26 | SQ Innovation AG | Pharmaceutical compositions of furosemide |
| CA3128033A1 (en) * | 2019-01-31 | 2020-08-06 | Scpharmaceuticals Inc. | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| US12042709B1 (en) * | 2022-02-22 | 2024-07-23 | Craig E. Williams | Fighting training device |
-
2014
- 2014-04-03 US US14/781,706 patent/US9884039B2/en active Active
- 2014-04-03 DK DK14778339.3T patent/DK2981258T3/da active
- 2014-04-03 SG SG10201709388QA patent/SG10201709388QA/en unknown
- 2014-04-03 EP EP14778339.3A patent/EP2981258B8/en active Active
- 2014-04-03 CA CA2908935A patent/CA2908935C/en active Active
- 2014-04-03 ES ES14778339T patent/ES2823589T3/es active Active
- 2014-04-03 EP EP20189271.8A patent/EP3799869B1/en active Active
- 2014-04-03 KR KR1020217018012A patent/KR102493735B1/ko active Active
- 2014-04-03 AU AU2014248164A patent/AU2014248164B2/en active Active
- 2014-04-03 SG SG11201508251RA patent/SG11201508251RA/en unknown
- 2014-04-03 PT PT147783393T patent/PT2981258T/pt unknown
- 2014-04-03 JP JP2016506607A patent/JP6415535B2/ja active Active
- 2014-04-03 EP EP25194100.1A patent/EP4696308A1/en active Pending
- 2014-04-03 CN CN201480031207.3A patent/CN105431145B/zh active Active
- 2014-04-03 KR KR1020157031677A patent/KR102266460B1/ko active Active
- 2014-04-03 MX MX2015014064A patent/MX367165B/es active IP Right Grant
- 2014-04-03 WO PCT/US2014/032800 patent/WO2014165660A1/en not_active Ceased
-
2015
- 2015-10-06 IL IL241917A patent/IL241917B/en active IP Right Grant
-
2018
- 2018-01-23 US US15/877,865 patent/US10272064B2/en active Active
- 2018-10-02 JP JP2018187299A patent/JP6677779B2/ja active Active
-
2019
- 2019-03-07 US US16/295,085 patent/US11433044B2/en active Active
-
2022
- 2022-08-05 US US17/817,729 patent/US12370168B2/en active Active
-
2025
- 2025-07-16 US US19/271,284 patent/US20250339397A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539921A5 (enExample) | ||
| JP2016034978A5 (enExample) | ||
| FI3685847T3 (fi) | Komplementtiaktiivisuuden modulaattoreita | |
| FI3310809T3 (fi) | Anti-cgrp-vasta-aineformulaatio | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| JP2016512564A5 (enExample) | ||
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| JP2016027060A5 (enExample) | ||
| JP2017014206A5 (enExample) | ||
| JP2018172440A5 (enExample) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX389336B (es) | Formulacion farmaceutica. | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| WO2012092305A3 (en) | Nanonized iron compositions and methods of use thereof | |
| MY204827A (en) | Semaglutide in medical therapy | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| EA201792144A1 (ru) | Стабильный препарат для парентерального введения тапентадола |